Dr. Anusha Kalbasi is a physician-scientist and radiation oncologist in the UCLA Department of Radiation Oncology and UCLA Jonsson Comprehensive Cancer Center. Dr. Kalbasi specializes in the treatment of sarcoma and melanoma. Dr. Kalbasi combines laboratory research with clinical trials to develop new ways to overcome resistance to immunotherapy. As a radiation oncologist, he is experienced in advanced approaches, including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), image-guided radiotherapy, and proton therapy.
Dr. Kalbasi earned his undergraduate and medical degrees with honors from UCLA and the David Geffen School of Medicine at UCLA, respectively, during which time he completed an HHMI-NIH research fellowship at the National Cancer Institute under Dr. Steven Rosenberg. He completed residency training in radiation oncology at the University of Pennsylvania, where he also completed a post-doctoral fellowship in tumor immunology under Dr. Gregory Beatty. He then completed a second post-doctoral fellowship in the laboratory of Dr. Antoni Ribas at UCLA, where he continued as a faculty member.
Dr. Kalbasi's research has been funded by the Conquer Cancer Foundation of ASCO, Radiological Society of North America, Tower Cancer Research Foundation, Sarcoma Foundation for America, Sarcoma Alliance through Research Collaboration, the Melanoma Research Alliance, the Damon Runyon Cancer Research Foundation, the UCLA CTSI KL2 Program and the National Institutes of Health (NCI).
Dr. Kalbasi leads an NIH-funded research effort that involves laboratory research and clinical trials, focused on overcoming resistance to immunotherapy, especially with respect to treatment of sarcoma and melanoma.
Clinical Trials Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)